| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|--------------------------|-------|--------------------------------------|-------|-------|----------------|-------|------------------------------|-------|-----------------------------------|-------|------------------------------------| | Year Ended December 31, 2022 \nReported GAAP measure | $ | Gross Profit \n331,080 | $ | Operating Expenses (a) ...

gilaxia Bioventus Inc. (NASDAQ:BVS) has emerged as an impressive turnaround story moving forward from its troubled post-IPO period where the company faced a major setback from its failed acquisition of "CartiHeal". The stock has more than doubled over the past year with the leader in therapeutic injections for osteoarthritis capturing a new round of operating momentum in recent quarters. Indeed, we last covered BVS back in October highlighting the improving outlook which was ultimately confirmed by a strong ...

DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the "Amendment") to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, ...

Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Tony Bihl - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Lilia-Celine Lozada - JPMorgan Bill Plovanic - Canaccord Operator Thank you for standing by. My name is Dustin, and I will be your conference operator today. This time, I would like to ...

Adjusted EPS Continuing Operations Operations (d) Costs incurred were the result of adopting restructuring plans to reduce headcount, reorganize management structure, and consolidate certain facilities. (h) Represents the loss on disposal of the Wound Business. 18 We present Adjusted EBITDA, Non-GAAP Gross Profit, Non-GAAP Gross Margin, Non-GAAP Operating Income, Non-GAAP Operating Expense, Non-GAAP Operating Margin, Non-GAAP R&D, Non-GAAP Net Income from continuing operations, and Non-GAAP Earnings per sha ...

Cash, cash equivalents and restricted cash as of September 30, 2023 totaled $26.8 million, compared to $30.2 million as of December 31, 2022. The decrease in cash was primarily due to the following: Table of Contents TABLE OF CONTENTS As used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to "Bioventus," "we," "us," "our," "the Company," and similar references refer to Bioventus Inc. and its consolidated subsidiaries, including Bioventus LLC ( ...

Bioventus Inc. (NASDAQ:BVS) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Dave Crawford - VP, IR Mark Singleton - SVP and CFO Chase Knickerbocker - Craig-Hallum Capital Group Robbie Marcus - JPMorgan Thank you for standing by, and welcome to Bioventus, Inc. Second Quarter 2023 Earnings Conference Call. Dave Crawford Tony will begin his remarks with an update on our business and outlook for the second half of the year, followed by a review of the quarter. Mark will offer further detail of our sec ...

Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our future financial results and liquidity; our ability to continue as a going concern; ...

Dave Crawford - VP, IR Tony Bihl - CEO Mark Singleton - SVP and CFO Operator I would now like to turn the conference over to Dave Crawford, Vice President, Investor Relations. Please go ahead. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncerta ...

Bioventus Inc. (NASDAQ:BVS) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Caitlin Cronin - Canaccord Operator Good day. And welcome to the Bioventus Incorporated Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Ins ...